Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing
(0:00) Introducing Eli Lilly CEO Dave Ricks (1:43) How Eli Lilly discovered the GLP-1 impact on weight loss, counterfeit products from China (7:08) GLP-1 pricing and capital allocation after a breakout pharma product (12:56) Why Biotech VC has plummeted, "patent hacking" in China (15:32) Dave's health regimen: good…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from All-In with Chamath, Jason, Sacks & Friedberg
See all episodes →
74%The Fight Over Open Source AI, Anthropic's $1.5B Payout, NYC Socialists: Evictions = Violence?
71%Can the AI Industry Regulate Itself? Stripe Wants PayPal, China Catches Up, NY Bans Datacenters
70%Eric Weinstein: The State of American Science, Breakthrough Coverups, and the Danger of Physics
Similar episodes from other shows
More like All-In with Chamath, Jason, Sacks & Friedberg →
Here's How the New Weight Loss Drugs Could Change Everything
Corner Office Conversation with Eli Lilly's Global CEO David Ricks
Healthcare is Broken—This Company Wants to Fix It
E193: GLP-1s, AI & the End of Sick Care: The Next $10B Health Tech Giant
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.